UNITY Biotechnology Announces Appointment of Clinical Development and Industry Veteran Gilmore O’Neill, M.B., to the Board of Directors
December 14, 2020 07:00 ET
|
Unity Biotechnology, Inc.
Nathaniel E. David, Ph.D., to step down from Management Team, but will remain on UNITY’s Board Changes Reflect Strategic Focus on Clinical Development in Age-Related Diseases of the Eye and Brain ...
UNITY Biotechnology, Inc. Reports Third Quarter 2020 Financial Results and Clinical Program Updates
November 04, 2020 16:01 ET
|
Unity Biotechnology, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of...
UNITY Biotechnology Announces First Patient Dosed in Phase 1 Study of UBX1325 in Diabetic Macular Edema
October 12, 2020 08:00 ET
|
Unity Biotechnology, Inc.
SAN FRANCISCO, Oct. 12, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing...
UNITY Biotechnology Announces Actions to Focus on Senolytic Programs in Ophthalmology and Neurology
September 15, 2020 08:00 ET
|
Unity Biotechnology, Inc.
- Corporate restructuring to extend cash runway through mid-2022 and key milestones - - UBX1325 to enter clinical development in patients with diabetic macular edema - SAN FRANCISCO, Calif., Sept. ...
UNITY Biotechnology to Participate in Upcoming September Investor Conferences
September 04, 2020 08:00 ET
|
Unity Biotechnology, Inc.
SAN FRANCISCO, Sept. 04, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing...
UNITY Biotechnology Announces Appointment of Lynne Sullivan as Chief Financial Officer
August 31, 2020 16:05 ET
|
Unity Biotechnology, Inc.
SAN FRANCISCO, Aug. 31, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing...
UNITY Biotechnology Announces 12-week data from UBX0101 Phase 2 Clinical Study in Patients with Painful Osteoarthritis of the Knee
August 17, 2020 07:00 ET
|
Unity Biotechnology, Inc.
UBX0101 failed to meet 12-week primary endpointGuidance for UNITY’s Bcl-xL inhibitor UBX1325 in retinal disease remains unchangedUNITY to focus senescence programs on ophthalmologic and neurologic...
UNITY Biotechnology Announces $80M Debt Financing From Hercules Capital
August 04, 2020 16:05 ET
|
Unity Biotechnology, Inc.
SAN FRANCISCO, Aug. 04, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing...
UNITY Biotechnology, Inc. Reports Second Quarter 2020 Financial Results and Clinical Program Updates
July 31, 2020 07:57 ET
|
Unity Biotechnology, Inc.
SOUTH SAN FRANCISCO, Calif., July 31, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing,...
UPDATE – UNITY Biotechnology, Inc. to Announce Second Quarter 2020 Financial Results
July 29, 2020 16:05 ET
|
Unity Biotechnology, Inc.
SAN FRANCISCO, July 29, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing...